Data study · analyzed July 2026

State of the Peptide Community 2026

We classified 2,896 posts from the peptide communities across Reddit, X, and PubMed — by what people are actually discussing, and which compounds dominate. The single biggest finding: the community is researching the next GLP-1 before it's approved.

Medically reviewed by Marko Maal, MSc Pharmacy · Source: the live community-signal feed

The takeaways

Key findings

  1. 1GLP-1s own the conversation — Tirzepatide, Retatrutide and Semaglutide are 3 of the 4 most-discussed compounds.
  2. 2The community is ahead of the regulator: retatrutide (not FDA-approved) is discussed more than semaglutide (Ozempic/Wegovy), which is.
  3. 3It's a dosing-and-experience culture — 67% of posts are personal experiences or dosing questions; only 7% are about side effects.
  4. 4GHK-Cu is the breakout non-GLP-1, the 4th most-discussed compound overall.
  5. 5Questions outnumber side-effect complaints nearly 2:1 — an information-seeking community, not a venting one.

Post intent

What the community talks about

Every post classified by intent. Two-thirds of the conversation is personal experience and dosing — not side effects or hype.

Personal experience
961 · 34%
Dosing / titration
932 · 33%
Direct questions
347 · 12%
Side effects
193 · 7%
Research / studies
163 · 6%
Vendor / sourcing
121 · 4%
Regulatory
62 · 2%

Most discussed

Top compounds by mention

Mentions across post titles and text. GLP-1s lead — and investigational retatrutide outranks approved semaglutide.

TirzepatideGLP-1/GIP · approved
311
RetatrutideTriple agonist · investigational
226
SemaglutideGLP-1 · approved
177
GHK-CuCopper peptide
152
TesamorelinGHRH analog
85
CJC-1295 / IpamorelinGH secretagogues
77
BPC-157Repair · research
75
SemaxNootropic
71
SelankAnxiolytic nootropic
57
MOTS-cMitochondrial
54
KPVAnti-inflammatory
50
CerebrolysinNeurotrophic
28
Melanotan-IIMelanocortin
22
TB-500Repair
21
SermorelinGHRH analog
20

Interpretation

Why it matters

The GLP-1 boom has spilled into a research-peptide community that is now studying the next drug — retatrutide — before approval. That gap between the conversation and the regulation is a genuine public-health and regulatory story.

The conversation is dominated by dosing uncertainty (a third of all posts), underscoring how little authoritative guidance exists for a fast-moving space — and the case for evidence-led, medically-reviewed resources over forum folklore.

Methodology

Posts were collected from public Reddit and X peptide communities and PubMed via public APIs, deduplicated, and each classified by intent (experience, dosing, question, side-effect, research, vendor, regulatory) and by compound mention. Compound counts are mentions across post titles and text; a single post can mention more than one compound. n = 2,896 classified posts (2,719 Reddit, 75 X, 102 PubMed). This is community signal, not clinical evidence — it measures what people discuss, not what works. Explore the live feed at /signal.

Cite this study: “State of the Peptide Community 2026,” My Peptide Story. mypeptidestory.com/signal/state-of-the-peptide-community-2026